HRP20210502T1 - Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1 - Google Patents

Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1 Download PDF

Info

Publication number
HRP20210502T1
HRP20210502T1 HRP20210502TT HRP20210502T HRP20210502T1 HR P20210502 T1 HRP20210502 T1 HR P20210502T1 HR P20210502T T HRP20210502T T HR P20210502TT HR P20210502 T HRP20210502 T HR P20210502T HR P20210502 T1 HRP20210502 T1 HR P20210502T1
Authority
HR
Croatia
Prior art keywords
image
alkyl
group
substituted
heteroaryl
Prior art date
Application number
HRP20210502TT
Other languages
English (en)
Croatian (hr)
Inventor
Jie Chen
Yan Chen
Ira B. Dicker
Richard A. Hartz
Nicholas A Meanwell
Alicia Regueiro-Ren
Sing-Yuen Sit
Ny Sin
Jacob Swidorski
Brian Lee Venables
Original Assignee
VIIV Healthcare UK (No.5) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIIV Healthcare UK (No.5) Limited filed Critical VIIV Healthcare UK (No.5) Limited
Publication of HRP20210502T1 publication Critical patent/HRP20210502T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/52Ortho- or ortho- and peri-condensed systems containing five condensed rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20210502TT 2016-02-04 2017-02-02 Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1 HRP20210502T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04
PCT/IB2017/050568 WO2017134596A1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
EP17704093.8A EP3411381B1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

Publications (1)

Publication Number Publication Date
HRP20210502T1 true HRP20210502T1 (hr) 2021-05-14

Family

ID=57995251

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210502TT HRP20210502T1 (hr) 2016-02-04 2017-02-02 Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1

Country Status (39)

Country Link
US (4) US10421774B2 (enExample)
EP (2) EP3411381B1 (enExample)
JP (1) JP6735837B2 (enExample)
KR (1) KR102795662B1 (enExample)
CN (1) CN109153700B (enExample)
AR (1) AR107512A1 (enExample)
AU (1) AU2017215529B2 (enExample)
BR (1) BR112018015629B1 (enExample)
CA (1) CA3013417C (enExample)
CL (1) CL2018002084A1 (enExample)
CO (1) CO2018008157A2 (enExample)
CR (1) CR20180387A (enExample)
CY (1) CY1124353T1 (enExample)
DK (1) DK3411381T3 (enExample)
DO (1) DOP2018000174A (enExample)
EA (1) EA036211B1 (enExample)
ES (2) ES2862325T3 (enExample)
HR (1) HRP20210502T1 (enExample)
HU (1) HUE054337T2 (enExample)
IL (1) IL260741B (enExample)
JO (1) JOP20170029B1 (enExample)
LT (1) LT3411381T (enExample)
MA (2) MA43960B1 (enExample)
MD (1) MD3411381T2 (enExample)
MX (1) MX375118B (enExample)
MY (1) MY199668A (enExample)
PE (1) PE20181355A1 (enExample)
PL (1) PL3411381T3 (enExample)
PT (1) PT3411381T (enExample)
RS (1) RS61746B1 (enExample)
RU (1) RU2716502C2 (enExample)
SG (1) SG11201806388XA (enExample)
SI (1) SI3411381T1 (enExample)
SM (1) SMT202100210T1 (enExample)
TW (1) TWI719126B (enExample)
UA (1) UA123867C2 (enExample)
UY (1) UY37109A (enExample)
WO (1) WO2017134596A1 (enExample)
ZA (1) ZA201805044B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20210347813A1 (en) 2018-04-24 2021-11-11 Viiv Healthcare Uk (No. 5) Limited Compounds with hiv maturation inhibitory activity
CA3164528A1 (en) 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
WO2025037232A1 (en) 2023-08-11 2025-02-20 ViiV Healthcare UK (No.4) Limited Tosylate salt form of a maturation inhibitor for treatment of hiv
CN121909019A (zh) 2023-09-27 2026-04-21 Viiv保健英国第三有限公司 药物组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
BR112012030818A2 (pt) 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
WO2011153319A1 (en) 2010-06-04 2011-12-08 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
HRP20151212T1 (hr) 2011-01-31 2015-12-04 Bristol-Myers Squibb Company C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
JP6001560B2 (ja) * 2011-01-31 2016-10-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−17およびc−3修飾トリテルペノイド
EP2791102B1 (en) * 2011-12-14 2016-05-18 Glaxosmithkline LLC Propenoate derivatives of betulin
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
EA027371B1 (ru) * 2013-02-06 2017-07-31 Бристол-Майерс Сквибб Компани C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
JP6186012B2 (ja) 2013-02-25 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
NZ724644A (en) 2014-04-11 2023-07-28 Viiv Healthcare Uk No 4 Ltd Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP4438041A3 (en) 2016-02-04 2025-01-01 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof

Also Published As

Publication number Publication date
EA201891649A1 (ru) 2019-02-28
US20190031709A1 (en) 2019-01-31
EP3411381A1 (en) 2018-12-12
MA43960B1 (fr) 2021-02-26
JOP20170029B1 (ar) 2021-08-17
ZA201805044B (en) 2020-08-26
HK1256866A1 (en) 2019-10-04
EP3831839B1 (en) 2023-07-26
UA123867C2 (uk) 2021-06-16
ES2862325T3 (es) 2021-10-07
MX2018009514A (es) 2018-09-05
AR107512A1 (es) 2018-05-09
CN109153700A (zh) 2019-01-04
BR112018015629B1 (pt) 2023-10-24
PL3411381T3 (pl) 2021-09-13
US11084845B2 (en) 2021-08-10
IL260741B (en) 2020-04-30
SMT202100210T1 (it) 2021-05-07
KR20180105229A (ko) 2018-09-27
PE20181355A1 (es) 2018-08-22
ES2957767T3 (es) 2024-01-25
US20210323997A1 (en) 2021-10-21
JP2019504104A (ja) 2019-02-14
CN109153700B (zh) 2021-03-09
WO2017134596A1 (en) 2017-08-10
EP3831839A2 (en) 2021-06-09
TW201739757A (zh) 2017-11-16
EA036211B1 (ru) 2020-10-14
CA3013417C (en) 2024-01-02
NZ744545A (en) 2025-03-28
DOP2018000174A (es) 2018-10-31
MA53358A (fr) 2021-07-21
SI3411381T1 (sl) 2021-04-30
MX375118B (es) 2025-03-06
RU2018130181A3 (enExample) 2020-03-05
RU2716502C2 (ru) 2020-03-12
EP3831839A3 (en) 2021-07-21
BR112018015629A2 (pt) 2018-12-26
CO2018008157A2 (es) 2018-08-21
CY1124353T1 (el) 2022-07-22
US20230295220A1 (en) 2023-09-21
UY37109A (es) 2017-09-29
TWI719126B (zh) 2021-02-21
AU2017215529A8 (en) 2018-08-30
AU2017215529B2 (en) 2019-01-31
RS61746B1 (sr) 2021-05-31
LT3411381T (lt) 2021-04-26
CL2018002084A1 (es) 2018-09-21
JP6735837B2 (ja) 2020-08-05
MA43960A (fr) 2018-12-12
AU2017215529A1 (en) 2018-08-23
MY199668A (en) 2023-11-15
RU2018130181A (ru) 2020-03-05
EP3411381B1 (en) 2021-01-20
PT3411381T (pt) 2021-03-18
DK3411381T3 (da) 2021-04-06
CR20180387A (es) 2018-09-20
CA3013417A1 (en) 2017-08-10
US20190359647A1 (en) 2019-11-28
SG11201806388XA (en) 2018-08-30
MD3411381T2 (ro) 2021-07-31
HUE054337T2 (hu) 2021-08-30
US10421774B2 (en) 2019-09-24
KR102795662B1 (ko) 2025-04-14

Similar Documents

Publication Publication Date Title
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
FI4219508T3 (fi) Substituoitu polysyklinen pyridonijohdannainen ja sen aihiolääke
HRP20221294T1 (hr) Neuroaktivni steroidi, njihovi pripravci i uporabe
JP2013527242A5 (enExample)
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
PE20190662A1 (es) Composiciones farmaceuticas que contienen derivados de piridona policiclicos sustituidos y profarmaco de los mismos
WO2016009065A3 (en) Quinoline derivatives for the treatment of inflammatory diseases
HRP20220899T1 (hr) Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba
PE20212077A1 (es) Nuevos compuestos sulfonamida de carboxamida
HRP20201645T1 (hr) Triterpenoidi s aktivnošću inhibiranja zrenja hiv, supstituirani na položaju 3 nearomatskim prstenom koji nosi halogenalkilni supstituent
HRP20181169T1 (hr) Predlijekovi fumarata i njihova upotreba u liječenju različitih bolesti
HRP20250181T1 (hr) Spojevi i postupci za ciljanu razgradnju receptora androgena
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
PE20142148A1 (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
HRP20250191T1 (hr) Derivati 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diona kao inhibitori alfa4beta7 integrina za liječenje upalnih bolesti
EA201591457A1 (ru) Терапевтические соединения
PH12016502147B1 (en) Substituted 4-phenylpiperidines, their preparation and use
SV2018005682A (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
JP2015078230A5 (enExample)
HRP20220920T1 (hr) Pirolo[1,2-f][1,2,4]triazini koji su korisni za liječenje infekcija respiratornim sincicijalnim virusom
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
HRP20211839T1 (hr) Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima
HRP20220683T1 (hr) Liječenje parkinsonove bolesti